Eighty-six women fulfilling specific selection criteria were studied for germline mutations in two breast cancer susceptibility genes, BRCA1 and BRCA2, using the protein truncation test (PTT). Nine germline mutations were identified, six in BRCA1 and three in BRCA2. Of the six BRCA1 mutations, three have previously been 
The most consistent factor associated with a woman ' BRCA1 and BRCA2 mutation analysis in early onset breastlovarian cancer patients For genomic DNA, patient peripheral blood lymphocytes (PBLs) were prepared from 10 ml EDTA blood and DNA was isolated using the salting out procedure.'0 Total RNA was pre- products were size separated using 12% sodium dodecyl sulphate polyacrylamide gel electrophoresis. Thereafter, the gels were fixed, dried, and exposed to Biomax film (Kodak, Rochester, NY).
Results
In this study 86 women were analysed using the protein truncation test for mutations in both BRCA1 and BRCA2. The results of BRCA1 years of age.14 Therefore it is to be expected that approximately half of the mutations would be the result of BRCA1 and half BRCA2. In this study the ratio of BRCA1 to BRCA2 mutations was 3:1, indicating that BRCA1 is more frequent in the Swiss population than BRCA2. Since, however, only a few mutations were detected, this result may be inaccurate owing to sample size.
Because of the size of BRCA1 and BRCA2, efficient screening of both genes remains problematical. The PTT represents a relatively useful alternative to more labour intensive screening strategies in that large amounts of coding sequence can be quite rapidly examined. A major advantage of this method, in comparison to other detection strategies, is that any changes observed are likely to lead to a loss of function. In this report cDNA was used as template for the PTT which is generated from mRNA by reverse transcriptase. Mutant message may be susceptible to the actions of nonsense mediated decay and therefore may not be represented to the same extent as normal message" which would result in the apparent absence of detectable truncated products by the PTT. This, we believe, is unlikely since before starting this study we investigated lymphoblastoid cell lines with known mutations that had previously been reported as being susceptible to the actions of nonsense mediated decay. These studies indicated that as long as mRNA was isolated from lymphocytes immediately after phlebotomy, sufficient mutant message was present for cDNA conversion and hence mutation detection (results not shown). An additional feature of the PTT which could lead to decreased sensitivity of the method is the amount of overlap between the respective segments used for gene analysis. If insufficient overlap is designed into the method, a loss of sensitivity is expected. The spectrum of disease observed in families harbouring BRCA2 mutations was different from that associated with mutations in BRCA1. It appears that mutations in BRCA2 may confer a broader range of disease susceptibility as compared to BRCA1. Indeed it has been shown that germline mutations in BRCA2 appear to be associated with pancreatic cancer development.2' In the current study we observed two melanoma patients within one family where only one isolated early onset breast cancer case was observed, suggesting that BRCA2 may confer increased risks for other types of cancer than breast and ovary. Unfortunately, DNA was not available for study from these two patients.
Two families from different regions of Switzerland were identified harbouring the same germline BRCA2 mutation (delACAA). As this 4 bp deletion is not discernible, owing to the nature of the surrounding sequence, from those reported at positions 3034 or 3035, it is difficult to determine if this region represents a common site for mutation or a founder mutation. Haplotyping analysis of the two families reported here suggests that these two families are related as common alleles are shared by all affected persons. Since this mutation has been previously described in families from different countries it remains possible that it is either a founder mutation or is a regional hotspot for mutations.
The 
